{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:25:35Z","timestamp":1764332735195},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Letermovir, a new viral terminase complex inhibitor, has been approved for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant patients. However, data on the efficacy and safety of letermovir for the treatment of CMV infection in transplant recipients remain scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We performed a single-center retrospective study of stem cell and organ transplant recipients who received letermovir for the treatment of CMV infection from November 2017 to October 2018.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>Six patients were included, and 5 were evaluable. All received letermovir in the context of a refractory or resistant CMV infection including asymptomatic CMV viremia (n = 3), CMV syndrome (n = 1), and CMV pneumonitis and colitis (n = 1). The 3 asymptomatic patients experienced a decrease of the viral load (VL) to &lt;200 IU\/mL after letermovir therapy. One patient displayed a partial VL response (2-log of VL reduction) but a good clinical response, and one who received a suboptimal dose of letermovir experienced an increase of viremia. There were no treatment-related adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>We demonstrate mixed efficacy in patients with refractory CMV infection suggesting that letermovir may be a useful therapeutic adjunct, potentially in combination with other antivirals.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000002785","type":"journal-article","created":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T11:52:11Z","timestamp":1558353131000},"page":"404-409","source":"Crossref","is-referenced-by-count":42,"title":["Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients"],"prefix":"10.1097","volume":"104","author":[{"given":"Pakpoom","family":"Phoompoung","sequence":"first","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada."},{"name":"Division of Infectious Disease and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor H.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jussi","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auro","family":"Viswabandya","sequence":"additional","affiliation":[{"name":"Hans Messner Allogeneic Transplant Program, University Health Network, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Humar","sequence":"additional","affiliation":[{"name":"Transplant Infectious Diseases, University Health Network, Toronto, ON, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation.","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1399-0012.2008.00942.x","article-title":"Hematologic complications of anti-CMV therapy in solid organ transplant recipients.","volume":"23","author":"Danziger-Isakov","year":"2009","journal-title":"Clin Transplant"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: first global approval.","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","article-title":"Targeting the terminase: an important step forward in the treatment and prophylaxis of human cytomegalovirus infections.","volume":"161","author":"Gentry","year":"2019","journal-title":"Antiviral Res"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation.","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2009.10.004","article-title":"A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes.","volume":"85","author":"Chevillotte","year":"2010","journal-title":"Antiviral Res"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance.","volume":"148","author":"Chou","year":"2017","journal-title":"Antiviral Res"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance.","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"e00922","DOI":"10.1128\/AAC.00922-18","article-title":"New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir.","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"e02337","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis.","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"e12965","DOI":"10.1111\/tid.12965","article-title":"Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).","volume":"20","author":"Chong","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246.","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transplant"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study.","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:06:40Z","timestamp":1696223200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000002785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000002785","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}